This is a once in a generation chance for Democrats to finally deliver on their promises to lower drug prices. At a time when the price of everything is going up, this bill, if enacted, would finally rein in big Pharma’s price-gouging and make medicines more affordable for millions of Americans.
Washington, DC – Yesterday, Representative Susan Wild, a champion for cutting costs for the people of Pennsylvania’s Seventh District, sent a letter signed by 19 colleagues, calling for Senate Majority Leader Chuck Schumer and Senate Committee on Finance Chairman Ron Wyden to provide relief for Americans by taking action to lower prescription drug prices through a reconciliation bill.
Continue reading “Representative Susan Wild Leads Colleagues in Calling on Senate to Lower Prescription Drug Prices”
Statement from Margarida Jorge, head of Lower Drug Prices Now – the leading campaign fighting to lower prescription drug prices – in response to House passage a bill to cap the cost of insulin:
This legislation is a positive step, but it falls far short of the kind of real reform that millions of Americans need for all kinds of health conditions.
Continue reading “LDPN on House Bill: “Half-measures are not enough.””
This report highlights what we already know: it is far past time for Congress to take immediate action to help lower the costs of everyday things in people’s lives. Congress can and should start with lowering drug prices, a policy that 9 out of 10 voters identify as important in the upcoming elections.
We are pleased that President Biden used his State of the Union Address to highlight the need to take action to lower the costs of prescription drugs. Our message to Democrats now is, get it done. Stop talking and start acting.
Today, Representative Susan Wild (PA-07) led a letter with 40 House Democrats addressed to leadership, urging them to take up legislative action as quickly as possible to lower drug prices.
Not only have Big Pharma corporations raised the prices of more than 450 drugs already this year, but this investigation from Senate Finance shows how they’re using complex loopholes to avoid paying taxes on the sales of those drugs.